Acute GVHD (aGVHD) is a major obstacle to allogeneic hematopoietic SCT (alloHSCT). Although it is thought that aGVHD is initiated in secondary lymphoid organs at a very early stage of alloHSCT, whether CD4 þ FOXP3 þ regulatory T-cells (Tregs) have an impact on aGVHD development during this period remains unclear. Here, we measured Tregs in peripheral blood as early as possible after HLA-mismatched alloHSCT, and assessed the incidence of aGVHD. Flow cytometric analyses revealed that at the second week after HSCT, patients with aGVHD had significantly (P ¼ 0.018) lower Treg:CD4 þ T-cell ratios than those without aGVHD. As these differences were seen before the development of aGVHD, these ratios can predict the incidence of aGVHD. The cumulative incidence of aGVHD in patients with ratios of o9% was significantly higher than that in patients with ratios of X9% (P ¼ 0.0082, log-rank test). Additionally, the specific ratio of Tregs:CD4 þ T-cells was the most significant value among all other possible lymphocyte-associated ratios and absolute cell counts. These findings suggest that the ratio of Tregs:CD4 þ T-cells at the second week post HLA-mismatched alloHSCT might be a potent predictor of aGVHD in these patients. The practical efficacy of this finding should be verified in further interventional studies.
INTRODUCTION
Although allogeneic hematopoietic SCT (alloHSCT) has the potential to cure many hematological disorders, GVHD continues to be a major obstacle associated with morbidity and mortality. Naturally occurring regulatory T-cells (Tregs) initially found in CD4 þ CD25 high T-cell fractions 1,2 suppress autoreactive 1 and alloreactive [3] [4] [5] immunoreactions. Other researchers have investigated the relationship between the frequency of CD3 þ CD4 þ CD25 high Tregs in peripheral blood and the incidence of GVHD after alloHSCT, but results have been inconsistent, possibly due to differences in the definition of CD25 high . [6] [7] [8] The intracellular protein derived from the FOXP3 gene has since been detected using flow cytometry, and is recognized as both a master regulatory gene and a unique marker for these Tregs. 9, 10 This procedure enables the specific measurement of Tregs, and distinguishes them from activated conventional CD4 þ CD25 þ T-cells. Subsequent studies have applied this procedure and suggested the role of Tregs in attenuating GVHD, mostly after HLA-matched alloHSCT.
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Here we examined Treg frequencies in the peripheral blood of patients who received alloHSCT from an HLA-mismatched related donor without T-cell depletion. As donor T-cells rapidly recover under our HSCT clinical protocol, 15, 16 we analyzed the frequencies of Tregs and other lymphocyte populations as early as possible following HSCT, and examined the relationship between Treg frequency and the subsequent incidence of acute GVHD (aGVHD).
PATIENTS AND METHODS

Patients and samples
Forty-seven patients who underwent alloHSCT from partially HLAmismatched related donors without T-cell depletion were evaluated. All patients received treatment at the Hyogo College of Medicine Hospital (Nishinomiya City, Japan) between July 2007 and August 2010 in accordance with the protocols approved by the institutional review board. Of these 47 patients, 45 received HLA-haploidentical HSCT. Patient characteristics are summarized in Table 1 . After the provision of written informed consent, peripheral blood samples were obtained weekly on a fixed day of the week from the first to the eighth week after transplantation. Data acquired between day 1 and 7 were accordingly defined as data of the first week, those between day 8 and 14 as data of the second week, and so on.
Transplant procedure
Thirty and seventeen patients were preconditioned with a nonmyeloablative and myeloablative regimen, respectively, as reported previously. 15, 16 In brief, the nonmyeloablative preparative regimen consisted of fludarabine (30 mg/m 2 /day, for 6 days), BU (3.2 mg/kg/day, for 2 days, i.v.), and either anti-T-lymphocyte globulin (Fresenius Biotech GmbH, Munich, Germany) or anti-thymocyte globulin (Genzyme, Cambridge, MA, USA) (8 mg/kg or 2-4 mg/kg of the total dose, respectively). The myeloablative preparative regimen consisted of fludarabine (30 mg/m 2 / day, 4 days), cytosine arabinoside (2 g/m 2 /day, 4 times over 2 days), CY (60 mg/kg/day, for 2 days) and TBI (8 Gy delivered in 4 fractions). The GVHD prophylaxis regimen for nonmyeloablative HSCT consisted of tacrolimus (0.02 mg/kg/day) and methylprednisolone (1 mg/kg/day), and that for myeloablative HSCT consisted of tacrolimus (0.03 mg/kg/day), MTX (10 mg/m 2 on day 1 and 7 mg/m 2 on day 3), methylprednisolone (2 mg/kg/ day) and mycophenolate mofetil (15 mg/kg). After transplantation, degrees of donor À recipient chimerism in T-cell and myeloid lineages of the peripheral blood were assessed by quantitative PCR for STR markers, as previously reported. 17 Assessment of aGVHD was based on clinical symptoms in accordance with commonly accepted criteria. 18, 19 Unless patient condition precluded them, skin, liver and gastrointestinal tract biopsies were performed to support the diagnoses. Gastric biopsy was essentially required for the diagnosis of gut GVHD without manifest diarrhea (stage 1).
Flow cytometric analysis of Treg
Peripheral blood samples were collected using EDTA anticoagulant, and PBMCs were isolated by density-gradient centrifugation for analysis without cryopreservation. Flow cytometric analysis was performed using a Coulter cytomics FC500 flow cytometer (Beckman Coulter, Fullerton, CA, USA) with CXP software (Beckman Coulter), using the following Abs: FITC-conjugated anti-CD3, phycoerythrin-Texas Red energy-coupled dye-conjugated anti-CD25, and phycoerythrin-Cy5-conjugated anti-CD4 (Beckman Coulter). For FOXP3 intracellular staining, the phycoerythrin-conjugated anti-FOXP3 Staining Set (eBioscience, San Diego, CA, USA) was used according to the manufacturer's instructions. FOXP3 staining was performed independently after staining with other Abs.
Statistical analysis
Differences in characteristics between patient groups were assessed by the Mann À Whitney U-test for continuous variables and the w 2 test for categorical values. Median Treg frequencies were compared using the Mann À Whitney U-test. Treg frequencies were adjusted for differences between patients with and without aGVHD by multiple regression with logistic analysis. The sensitivity and specificity of Tregs in predicting aGVHD were assessed by receiver operating characteristic curve analysis. Cumulative incidences of aGVHD were plotted according to the Kaplan À Meier method and compared using the log-rank test.
RESULTS
Patients
Of the 47 patients, 22 presented with aGVHD vs 25 who did not ( Table 1 ). The onset of aGVHD occurred at a median of 38 days after transplantation (range: 14-102). None of the characteristics examined had any significant impact on aGVHD incidence. As described previously, the degree of donor À recipient chimerism in T-cell and myeloid lineages of the peripheral blood achieves the complete donor type within 2 weeks after HLA-mismatched HSCT in our hospital. [15] [16] [17] Here, assessment once per week confirmed that on average complete donor-type chimerism in T-cells was achieved on day 10 (median, range: 5-23). Lymphocytes recovered during the second week ( Figure 1 ) were therefore considered to consist almost entirely of donor-originated lymphocytes.
Flow cytometric analysis of Tregs Representative results of a patient 4 weeks after HSCT are shown in Figures 2a-d. FOXP3
þ Tregs were analyzed using a flow cytometric plot gated by CD3 þ CD4 þ fractions ( Figure 2a ). Although CD25 staining alone showed a large overlap between CD25 þ and CD25 À cells (Figure 2c ), FOXP3 staining was able to separate FOXP3 þ cells as an isolated population ( Figure 2d ). As demonstrated previously, CD25 staining alone is frequently incapable of revealing an unequivocal boundary that discriminates Tregs from CD4 þ CD25 þ -activated conventional T-cells in almost all cases. 20 As FOXP3 staining has apparent objectivity and, moreover, FOXP3 is the key molecule for this type of Treg, 9,10 we defined Tregs simply as CD4 þ FOXP3 þ T-cells, regardless of CD25 expression.
Treg:CD4
þ T-cell ratios at the second week were significantly lower in patients with aGVHD As lymphocyte numbers were markedly low during the first week, as shown in Figure 1 , flow cytometric analysis was unable to detect any Tregs. By the second week after HSCT, in contrast, lymphocyte numbers increased to levels that made analysis possible in almost all cases (41 of 47 patients). Representative results of patients without and with aGVHD are shown in Figures 2e and f, respectively. Of the remaining six patients with slower lymphocyte recovery, two could be assessed at the third week, one at the fifth week, one at the sixth week and two at the seventh week. Figure 3 shows Treg:CD4 þ T-cell ratios after HSCT (n ¼ 41), which are the most meaningful values as described in the following paragraph. On average, Tregs were collected on day 12 (median, range: 8-14) during the second week. Patients with aGVHD had significantly lower ratios in the second week after HSCT than those without aGVHD (median (range), 5.23 (0.32-44.8) vs 15.5 (0.00-37.1); P ¼ 0.018). Similar tendencies were seen during the following weeks, but the differences were not statistically significant. Multivariate analysis using logistic regression, which incorporated patient characteristics and transplantation settings, showed that Treg:CD4 þ T-cell ratio was a unique independent and significant factor related to the incidence of aGVHD (Table 2) .
þ T-cell ratio is the most significant value among all other ratios and absolute counts We also examined the significance of all other ratios between two major lymphocyte populations during the second week. As summarized in Table 3A, Treg frequency at early stages predicts aGVHD T Fujioka et al
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þ T-cell:CD4 þ T-cell ratio (median (range), 1.98 (0.43-9.79) in the aGVHD ( þ ) group vs 4.13 (0.38-32.3) in the aGVHD ( À ) group; P ¼ 0.043) were significant, the Treg:CD4 þ T-cell ratio (P ¼ 0.018) had statistically the most significant value. Additionally, neither absolute numbers of whole lymphocytes nor the respective lymphocyte fraction (including Tregs) significantly correlated with the incidence of aGVHD (Table 3B) .
Treg:CD4
þ T-cell ratio at the second week predicts the incidence of aGVHD As aGVHD occurred at a median of 38 days after HSCT (range, 14-102), while the significant decreases in Treg:CD4 þ T-cell ratio were observed during the second week, this ratio can serve to predict the incidence of aGVHD. A receiver operating characteristic curve was generated by plotting the true positive rate of aGVHD against the false-positive rate for different cutoff-ratio values (Figure 4 ). The area under the curve was 0.73, indicating that the Treg:CD4 þ T-cell ratio at the second week is a good predictor of aGVHD. Further analysis revealed that a cutoff-ratio value of 9% yielded the most accurate predictions of future aGVHD incidence (Figures 4, 69 .6% sensitivity and 77.8% specificity). Treg:CD4 þ T-cell ratios of o9% predicted a significantly higher incidence of aGVHD than ratios of X9% ( Figure 5 , P ¼ 0.0082, log-rank test).
DISCUSSION
In this study, we found that ratios of Treg:CD4 þ T-cells during the second week after HLA-mismatched HSCT without T-cell depletion accurately predicted the incidence of future aGVHD. Other investigators have used flow cytometry with intracellular staining of FOXP3 to demonstrate a relationship between aGVHD and Treg frequency in peripheral blood. Rezvani et al.
11 demonstrated a significant decrease in Treg frequencies at days 30 and 45 when comparing patients with and without aGVHD at the time of Treg sampling, as did Ratajczak et al.
14 at a mean of 3 months. Furthermore, Magenau et al. 13 assessed Tregs at the onset of aGVHD and demonstrated significant decreases in Treg frequencies in aGVHD patients, with comparison done using samples at GVHD onset and from patients without GVHD, such that the two groups were balanced for the time of acquisition. While their study sampled Tregs more than 4 weeks post transplantation, our study reports significant differences at less than half this time. Although further investigation is needed to determine whether early-stage Treg measurements are possible in other alloHSCT settings, our method under the condition of HLAmismatched HSCT with rapid hematopoietic reconstitution [15] [16] [17] Receiver operating characteristic (ROC) analysis. ROC curve for the ratios of Tregs:CD4 þ T-cells in identifying patients with aGVHD. The dashed diagonal line represents non-discrimination. Arrow, cutoff ratio at which the sensitivity and specificity resulted in a maximal Youden's index (cutoff ratio, 9%; sensitivity, 69.6%; specificity, 77.8%).
produced the earliest reported differences in Treg frequency, a finding with practical applications that allows for the prediction of future incidence of aGVHD.
It is a commonly accepted theory that GVHD is initiated in the priming phase, in which donor T-cells activate and proliferate in response to host APCs in secondary lymphoid organs, 21 where Tregs presumably function effectively by suppressing APC function. 22 TNFa is also well known as a central cytokine that peaks immediately after HSCT and stimulates APCs to prime T-cells during this phase. 21, 23 Choi et al. 24 and Willems et al. 25 have both demonstrated that levels of TNFa receptor 1 (a surrogate marker of TNFa) at day 7 correlate with subsequent development of GVHD after myeloablative and nonmyeloablative alloHSCT, respectively. Although a number of studies using animal models have contributed to theories underlying GVHD pathogenesis, [26] [27] [28] [29] [30] their finding that this priming phase is limited to a very short duration immediately after HSCT in humans is particularly valuable. The most important point in our study is that conducting investigations at the earliest possible time point after HSCT enabled us to obtain our findings from a very narrow time window. Although it remains unclear whether lower Treg frequencies in peripheral blood reflect lower frequencies in secondary lymphoid organs, integrating our findings and previous studies in which the decline in Treg frequency in peripheral blood was seen during the initial phase of GVHD, 31 it is reasonable to assume that this is indeed the case, and thus that it causes the development of GVHD.
We also found that while absolute numbers of each lymphocyte population did not predict the occurrence of aGVHD, the Treg:CD4 þ T-cell ratio was the most significant predictor among all other ratios ( Table 3) . As Tregs can work in cooperation with other cells, including APCs and other T-cells, 22 it is considered rational that ratio rather than absolute number is the relevant factor for predicting aGVHD. However, the reason why the specific ratio of Tregs:CD4 þ T-cells is the most significant predictor remains uncertain. Although CD4 þ T-cells recognize MHC class II molecules and have been shown to induce GVHD in a class II-mismatched (class I-matched) murine HSCT model, 32 the importance of CD4 þ T-cells in GVHD pathogenesis has been demonstrated in fully MHC-mismatched (both class I and class II) murine models [33] [34] [35] and even in an HLA class I-mismatched HSCT. 36 Beilhack et al. 33 visualized initial proliferation of CD4 þ T-cells followed by CD8 þ T-cells in secondary lymphoid organs, and Ewing et al. 34 and Yu et al. 35 have demonstrated that the activity of CD4 þ T-cells in the early phase contributes to subsequent development of aGVHD by CD8 þ T-cells. Accordingly, CD4
þ T-cells would likely have a leading role during the priming phase of aGVHD, and only then would activation and proliferation of CD8 þ T-cells proceed. Our observation that both higher CD4 þ T-cell:whole T-cell and lower CD8 þ T-cell:CD4 þ T-cell ratios in the second week exhibit a significant relationship with aGVHD development does not conflict with these findings, as they both indicate a greater abundance of CD4 þ T-cells than CD8 þ T-cells. Furthermore, CD4
þ T-cells have a particularly direct relationship with Tregs, with CD4 þ T-cells being the principal targets that Tregs suppress in APC-dependent 37 and -independent 38 manners. Considering this, the high significance of the Treg:CD4 þ T-cell ratio is reasonable.
Whereas 22 patients developed aGVHD in this study, half of those had grade 1 aGVHD. As previously described, 15 once aGVHD appears in these HLA-mismatched HSCT cases, it inevitably and rapidly progresses to more severe disease, resulting in fatal outcome. All the 11 patients with grade I aGVHD had stage 1 or 2 skin disease at onset. We were therefore obliged to treat them at the earliest time possible, usually within 24 h, with a combination of topical treatment and dose escalation of internal corticosteroid as initial treatment. Additionally, in cases where a skin biopsy was performed, we were unable to delay treatment while waiting for the results, although they would have been helpful for subsequent validation of treatment. Consequently, the disease remained at grade 1 in half of the patients, whereas progression could not be prevented in the other half. It is notable that Treg:CD4 þ T-cell ratios are able to predict even mild cases of aGVHD, as even grade 1 aGVHD poses a high risk of causing more serious conditions, and should be avoided if possible. In contrast to previous studies, 13, 14 we did not observe a significant inverse relationship between aGVHD grade and Treg:CD4 þ T-cell ratio (data not shown). We attribute this to the early intervention and/or unequal distribution of patients for each grade.
We have demonstrated that patients who developed aGVHD had significantly lower Treg:CD4 þ T-cell ratios at the second week after HLA-mismatched HSCT, well in advance of clinical aGVHD symptoms. The measurement of Tregs during the second week therefore provides a means to predict the development of aGVHD. Our results suggest that Tregs have a vital role in regulating aGVHD progression, and support the efficacy of early infusions of donor Tregs to prevent GVHD in HLA-haploidentical HSCT. 39 Further studies are needed to confirm whether interventions lead to improved outcomes for patients who show a high risk of aGVHD during the second week post HSCT. T-cell ratios o9% had a significant higher incidence of aGVHD than those with ratios X9% (P ¼ 0.0082, log-rank test). Measurements were taken in the second week after HSCT.
